What is Poseida Therapeutics?
Founded in 2014 and headquartered in California, Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of transformative cell and gene therapies. The company leverages its unique technology platforms, including non-viral gene engineering and piggyBac DNA modification, to create highly effective treatments for patients suffering from blood cancers and solid tumors. By focusing on precision medicine, Poseida aims to overcome the limitations of current therapeutic modalities, positioning itself as a key innovator in the next generation of oncology treatments.
How much funding has Poseida Therapeutics raised?
Poseida Therapeutics has raised a total of $566.3M across 8 funding rounds:
Series A
$23M
Private Equity
$11.2M
Unspecified
$19.8M
Series B
$30.5M
Series C
$142M
Series D
$110M
Stock Offering
$204.8M
Share Placement
$25M
Series A (2015): $23M with participation from Malin Corporation Plc
Private Equity (2017): $11.2M, investors not publicly disclosed
Unspecified (2017): $19.8M supported by California Institute of Regenerative Medicine
Series B (2018): $30.5M featuring Tavistock Life Sciences, Malin Corporation plc, Vivo Capital, and Longitude Capital
Series C (2019): $142M backed by Longitude Capital, Malin Corporation plc, Pentwater Capital Management, Perceptive Advisors, Aisling Capital, Boxer Capital, Vivo Capital, and Novartis Pharma
Series D (2020): $110M with participation from Fidelity Management Research Company, Adage Capital Management, and Schonfeld Strategic Advisors
Stock Issuance/Offering (2020): $204.8M, investors not publicly disclosed
Share Placement (2023): $25M supported by Astellas Venture Management
Key Investors in Poseida Therapeutics
Longitude Capital
A healthcare-focused venture capital firm that invests in biotechnology and medical technology, pairing sector expertise with flexible capital to help innovators scale.
Perceptive Advisors
A New York-based investment firm managing significant assets with a specialized focus on funding innovative healthcare and life sciences technologies.
Aisling Capital
A leading investment firm specializing in biopharmaceutical development and commercialization, with a focus on genomically defined cancers and transformative healthcare solutions.
What's next for Poseida Therapeutics?
With the recent capital injection, Poseida Therapeutics is well-positioned to prioritize the advancement of its lead clinical candidates through critical regulatory milestones. The strategic focus will likely center on expanding its manufacturing capabilities and refining its gene delivery systems to enhance therapeutic efficacy and safety profiles. As the company moves deeper into its clinical lifecycle, the emphasis will shift toward data readouts that validate its platform's potential to deliver durable responses in patients with high-risk malignancies. Continued fiscal discipline and strategic partnerships will remain essential as the firm transitions toward potential commercialization and long-term value creation in the global healthcare market.
See full Poseida Therapeutics company page
